Scientific Industries Q2 2025 Earnings Report

Scientific Industries EPS Results

• Actual EPS: -$0.13
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Scientific Industries Revenue Results

• Actual Revenue: $2.33 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Scientific Industries Announcement Details

• Quarter: Q2 2025
• Date: 8/19/2025
• Time: After Market Closes
• Conference Call Date: Wednesday, August 20, 2025
• Conference Call Time: 11:00AM ET

Scientific Industries (OTCMKTS:SCND), Inc. (OTCMKTS:SCND) is a manufacturer and distributor of laboratory equipment and life science research tools. The company specializes in the design, development and production of sample mixing and handling instruments, including vortex mixers, tube shakers, decappers and digital homogenizers. These products are employed across a range of settings such as academic research laboratories, pharmaceutical and biotechnology firms, clinical diagnostic centers and industrial quality-control facilities.

Since its inception in the mid-20th century, Scientific Industries has focused on durability, precision and user-friendly design in its portfolio. Its flagship product line, the Vortex-Genie series, has become a mainstay in laboratories worldwide for reliable mixing of reagents and cell suspensions. Over time, the company has expanded its offering to include automated tube decappers, microplate mixers and digital shaker systems, aiming to streamline routine sample-preparation workflows and enhance reproducibility in experimental protocols.

Headquartered in Bohemia, New York, Scientific Industries serves customers throughout North America and maintains distribution partnerships in Europe, Asia and other global markets. The company’s leadership team draws on decades of industry experience in engineering and life sciences, guiding product innovation and customer support. By combining in-house manufacturing capabilities with a network of technical representatives, Scientific Industries seeks to maintain close engagement with end users and deliver support across diverse geographies and research applications.

Scientific Industries Q2 2025 Earnings Call Transcript

Key Takeaways

• Positive Sentiment: The company completed the sale of its legacy Genie products division to Mettler Toledo’s Ohaus division, marking a strategic pivot away from its 70-year-old core brand to fund new growth initiatives.
• Positive Sentiment: Scientific Industries is focusing on its future as a pioneer of AI-powered life science platforms, starting with its vivid computer vision-based automated pill counters and a subscription-driven monetization model.
• Positive Sentiment: Q2 R&D milestones include optimized nanoparticle-based dissolved oxygen sensors, improved biomass and pH sensing technologies, an advanced liquid injection system, and a new BioArP Pro sensor, driving several near-term product launches.
• Negative Sentiment: The broader lab tools and bioprocessing sector remains subdued, with softer order volumes, extended procurement cycles, and Q2 revenue approximately $140,000 below last year as academic and early-stage biotech spending tightened.
• Positive Sentiment: Despite market headwinds, lead generation is up 35%, with deepening strategic engagements at Genentech, Amgen, Biogen, and J&J, plus independent peer-review validation and industrial customer successes bolstering the commercial funnel.

Presentation

[Operator]

Good day, and welcome to the Scientific Industries Second Quarter Fiscal Year twenty twenty five Financial Results Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Joe Doramey, Managing Partner. Please go ahead.

[Joe Dorame, Managing Partner at Lytham Partners]

Thanks, Michael. Good morning and thank you all for joining us today to review Scientific Industries' financial results for the 2025 ended 06/30/2025. With us today on the call are Helena Santos, Chief Executive Officer Daniel Donady, CEO of SBI and John Moore, Chairman. After the conclusion of today's prepared remarks, we'll open the call for questions. Before we begin with prepared remarks, I would like to remind everyone certain statements made by the management team of Scientific Industries during this conference call constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

[Joe Dorame, Managing Partner at Lytham Partners]

Except for the statements of historical fact, this conference call may contain forward looking statements that involve risks and uncertainties, some of which are detailed under Risk Factors in documents filed by the company with the Securities and Exchange Commission, including the annual report on Form 10 ks for the year ended 12/31/2024. Forward looking statements speak only as of the date the statements were made. The company can give no assurance that such forward looking statements will prove to be correct. Scientific Industries does not undertake and specifically disclaims any obligation to update any forward looking statements, except as required by law. Now I'd like to turn the call over to Helena Santos, CEO of Scientific Industries. Helena?

[Helena Santos, CEO at Scientific Industries]

Thank you, Joe, and thank you everyone for joining us today. This really is a historic time for our company where a seventy year old chapter closes and a new one begins. Two weeks ago tomorrow, we sold our legacy Genie products division to a respected player in our industry, the O House division of Mettler Toledo. Scientific Industries was founded on the promise that it had invented a unique product, and by the standards at that time, innovative and market worthy. And to its testament, the Vortex Genie is still today one of the most widely recognized and respected brands in the lab equipment industry.

[Helena Santos, CEO at Scientific Industries]

I want to take this opportunity to thank just some of our dedicated team that helped create and nurture a product line that is known for excellence and quality and service. Mr. Robert Nichols, our division president, Ms. Deborah Siegel, our VP of Sales and Marketing, and all the people behind the scenes who love the Genies and have gone above and beyond what's expected of them. These individuals will always be honored as part of the company's history.

[Helena Santos, CEO at Scientific Industries]

We've welcomed new friends from L House into our lives, and jointly, we've made a commitment to ensure that the Genie customers and suppliers will receive the same quality products that has made the Genie name a trusted brand. This was an important targeted strategic step to enabling the next chapter in our company's history. One that will define the future of scientific industries. So what is the future of scientific industries? How do we define the future for ourselves?

[Helena Santos, CEO at Scientific Industries]

Just like we were pioneers in vortexing technologies, we see ourselves as pioneers of AI powered life science platforms. Starting with our vivid computer vision based automated pill counters, where we will focus on machine learning capabilities, features innovation, and subscription monetization. This roadmap will place us in the forefront of pill counting technology and ultimately providing shareholder value. Our Torvald division, which will continue to operate out of here in Bohemia, provides solid and predictable cash flows with realistic opportunity for growth. Next, and perhaps the more important platform for many of our shareholders, is our bioprocessing division, which is getting close to realizing its potential with the expectation of some very important product development milestones coming up, as Mr. Daniel Donadilla would discuss right after me. And finally, I would like to thank our shareholders for their unwavering support throughout our journey and evolution. None of this would be possible without you. I thank you and I now turn it over to Daniel. Daniel?

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

Thanks, Helena, and good afternoon, everyone from Germany. As we move to the 2025, the broader laboratory tools and bioprocessing sector continues to face a subdued operating environment. Across the board, peers such as Sartorius, Thermo Fisher and Danaher have reported softer order volumes, extended procurement cycles and capital conservatism, especially in academic and early stage biotech settings. These headwinds are well recognized and largely macro driven, shaped by tight research budgets, lingering uncertainty in biotech funding and ongoing prioritization of cash efficiency across the value chain. At Scientific Bioprocessing, we see a very similar picture.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

Revenue softness remains a short term reality, but one that does not reflect the lack of demand. Instead, we continue to experience a clear and growing wave of customer engagement, trial activity and long term strategic dialogue. The shift towards integrated, data rich and digitally connected bioprocessing solutions is not only progressing, it's accelerating behind the scenes. And this shift plays directly into our strength. Our technology is designed for a new era of bioprocessing, one where labs must move faster, generate deeper insights and be more innovative at lower costs.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

That's why even as the external market remains cautious, we are staying focused on execution. This is a period of platform technology completion, real world validation and commercial activation. We are confident that the momentum we're building today through increased customer interest, strong top of the funnel performance and rapid product development will translate into growth as market activity normalizes. Let me dive into the business and begin on the R and D side, where Q2 marked focused meaningful progress across all major development tracks of the DORTS platform. In dissolved oxygen sensing, we advanced our nanoparticle based PIL technology through a comprehensive optimization phase.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

This included improvements in formulation, freeze drying protocols, beta sterilization and external compatibility testing. We validated performance in both Baffet Microbial Shake Flask and mammalian systems and are now preparing for market launch in Q3 to drastically expand the applicability of our technology into segments that have been inaccessible so far. For biomass monitoring, we achieved a significant milestone with major improvements in measurement accuracy under highly turbulent conditions, such as baffle flask as well as under mammalian cell culture conditions. Enhanced pill rejection algorithms, particularly at low cell densities, resulted in strong accuracy gains across microbial cultivations and mammalian cultures. These improvements were verified in pilot studies and culminated in a successful market launch of improved biomass monitoring in Q2.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

In pH sensing, which is very important and core to our technology strategy, we continue to push toward a wide range measurement capability. Both nanoparticle and pure based chemosensor formats were advanced, supported by algorithmic optimization, electronics enhancements and calibration simplification. Internal lab validation is ongoing and pilot evaluations are scheduled to begin in Q4. Our List two liquid injection system also advanced in several key areas. We completed design studies, component development and early stage hardware handling tests.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

Based on extensive user feedback, we initiated a hardware redesign to prioritize simplicity and usability while still delivering Bioreactor grade functionality in a shake flask environment. Although this introduces a short delay, it reflects a stronger alignment with real world and particularly industrial needs. A new patent application was also filed this quarter to protect our high precision dispensing technology for shaking systems. With the BioArp Pro, our miniaturized biomass sensor for stirred bioreactors, we made clear technical progress this quarter. We finalized the hardware redesign focused on bubble rejection and miniaturization, completed electronics and firmware prototypes and initiated lab testing.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

Based on the encouraging results from these early evaluations and clear interest from the market, we've now formally added the Bio R to our R and D and product launch road map. We see strong potential here to address long standing sensing gaps in high throughput Bioreactor applications, and we are treating it as a strategic extension of our core offering. In glucose sensing, we also saw significant advances. Enzyme stabilization improved more than tenfold, enabling us to expand work on both Till and Flowserve formats. Based on our modular enzymatic platform, we were able to further prototype and add a LACTIC sensor to the pipeline this quarter with first proof of concept studies successfully completed, reinforcing our confidence in enzymatic chemo sensing as a versatile technology base for future applications even beyond glucose and lactate.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

Lastly, our DOT software platform continued to evolve with back end updates that support broader sensor integration, more efficient calibration workflows and scalable data processing. These infrastructure improvements ensure that everything we're developing can be deployed and scaled with confidence in customer environments. In summary, on the R and D side, Q2 was a strong quarter of execution across our pipeline, advancing key technologies towards commercial readiness while expanding the road map in direct response to customer demand and real world performance. Turning to the commercial side. Despite a difficult market environment, we continue to see strong engagement with our technologies across the board.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

Lead generation is up 35% year to date, and both Q1 and Q2 track fully in line with our commercial targets for 2025. This reinforces the sustained relevance of our product vision in the market and the depth of customer interest across application areas. At the same time, the impact of broader market condition remains visible, particularly when it comes to capital conversion. Scientific conferences, which have traditionally been one of our, if not the most effective engagement channel, are experiencing lower in person attendance due to tighter travel and event budgets. This has reduced immediate conversion opportunities even though top of the funnel demand remains strong.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

More broadly, we continue to see conservative investment behavior across both academia and biotech. Academic labs are facing reduced federal funding, while early stage biotech remains challenged by a cautious financing environment and continued pricing policy debates, particularly in The U. S, primarily resulting in longer purchasing cycles and greater selectivity in capital projects. This effect obviously translates into our numbers. While Q2 revenue was up 66% compared to the soft Q1, it remained approximately $140,000 below the same quarter last year.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

Academic sales, which represented 24% of total revenue in 2024, account for only 6% year to date. As a result, a number of pipeline opportunities originally expected to close in 2025 have now shifted into 2026 and beyond. Both the current and next year's pipelines reflect that reality. At the same time, improvements in operational efficiency have contributed to cash consumption that is fully in line with our 2025 targets and below that of the same period in 2024. Having said that, we are also seeing several reasons for optimism.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

Firstly, engagement with leading biopharma companies is deeper than ever. Since the launch of our mammalian cell culture line in Q1, we've initiated product rights with Genentech, Amgen, Biogen and Johnson and Johnson, just to name a few, companies that represent major strategic opportunities, and we're optimistic about converting these engagements into commercial agreements. Secondly, our technology continues to earn third party validation. In April, the leading European technical university in Aachen published a peer reviewed study confirming the performance advantages of our DO sensor PID and MPS sensor over established reference methods. This kind of independent data is crucial for driving adoption, especially in regulated or innovation conservative environment.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

And lastly, Q2 delivered the first significant industrial customer success story from Brain. Together, we demonstrated that the O based feeding in modern shake glass improves simulation of bioreactor conditions during early strain screening. The results not only validate our approach, but point to meaningful reductions in reliance on bioreactor runs. We are particularly excited that Brain AG plans to present these findings at RAFT twenty twenty five, the leading fermentation technology conference in November in The U. S.

[Daniel Donadille, President & CEO at Scientific Bioprocessing]

So while the market continues to place some friction between interest and close orders, the quality of our engagement, the strength of our funnel and the momentum behind our platform give us confidence. As market conditions improve, we believe we are well positioned to convert today's interest into tomorrow's growth. Until then, our focus remains on high quality execution, close customer collaboration and thoughtful scaling, so that when the market rebounds, we are ready to capture it. And with that, I hand the call back to Joe.

[Joe Dorame, Managing Partner at Lytham Partners]

Thanks, Daniel. Michael, we're ready to take any questions. Can you please provide instructions for folks to queue up?

[Operator]

Certainly. We will now begin the question and answer session. Seeing no questions, this concludes the question and answer session. I would like to turn the conference back over to John Moore for any closing remarks.

[John Moore, Chairman at Scientific Industries]

Thank you. Scientific Industries was founded over seventy years ago to solve an important twentieth century problem, reproducibility in lab experiments through the invention of the Vortex Genie mixer. The company developed an iconic product, was used in virtually every life science lab in the world. However, we acquired many competitors and over the seventy years the company was challenged to deliver satisfactory shareholder returns. Over the last five years, we began to transition the company to transform this small but iconic company to solve important big twenty first century problems like farmageddon, challenges in pharmacy productivity and small scale to large scale scale up in the synthetic biology industry.

[John Moore, Chairman at Scientific Industries]

We believe that solving these problems is going to dramatically improve our ability to be able to create shareholder returns by changing the complexion of the company to selling not only hardware, but also subscription software and single use sensor technology. So we appreciate the support from our shareholders. We're excited about this historic transformation. We're grateful to Helena for having managed the transformation sale of the company to the product line to Mettler Toledo, and we're looking forward to the future.

[Operator]

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

Participants

Executives

• Helena Santos, CEO
• John Moore, Chairman

Analysts

• Joe Dorame, Managing Partner at Lytham Partners
• Daniel Donadille, President & CEO at Scientific Bioprocessing